<DOC>
	<DOCNO>NCT00877760</DOCNO>
	<brief_summary>The purpose study investigate whether possible augment response patient HBeAg-positive chronic hepatitis B entecavir use temporary peginterferon alpha-2a add-on strategy</brief_summary>
	<brief_title>Augmenting Response Entecavir With Peginterferon a-2a Treatment HBeAg-positive Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>Chronic hepatitis B ( HBsAg positive &gt; 6 month ) HBeAg positive , antiHBe negative screening ALT &gt; 1.3 x ULN within 60 day prior screen screen Liver biopsy perform within 2 year prior screen screen Age &gt; 18 year Written inform consent Adequate contraception male females treatment follow ; negative pregnancy test ( woman childbearing potential ) Antiviral therapy HBV within previous 6 month Treatment investigational drug within 30 day screen Previous treatment lamivudine telbivudine six month Severe hepatitis activity document ALT &gt; 10 x ULN History decompensated cirrhosis ( defined jaundice presence cirrhosis , ascites , bleed gastric esophageal varix encephalopathy ) Preexistent neutropenia ( neutrophils &lt; 1,500/mm3 ) thrombocytopenia ( platelet &lt; 90,000/mm3 ) Coinfection hepatitis C virus human immunodeficiency virus ( HIV ) Other acquire inherited cause liver disease ( i.e . alcoholic liver disease , obesity induce liver disease , drug relate liver disease , autoimmune hepatitis , hemochromatosis , Wilson 's disease alpha1 antitrypsin deficiency ) Alpha fetoprotein &gt; 50 ng/ml Hyper hypothyroidism ( subject require medication maintain TSH level normal range eligible inclusion/exclusion criterion meet ) Immune suppressive treatment within previous 6 month Contraindications alphainterferon therapy like suspect hypersensitivity interferon PEGinterferon know preexist medical condition could interfere patient 's participation completion study . Pregnancy , lactation Other significant medical illness might interfere study : significant pulmonary dysfunction previous 6 month , malignancy skin basocellular carcinoma previous 5 year , immunodeficiency syndrome ( e.g . HIV positivity , autoimmune disease , organ transplant cornea hair transplant ) Any medical condition requiring , likely require chronic systemic administration steroid , course study Substance abuse , alcohol ( &gt; 80 g/day ) , I.V . drug inhale drug past 2 year . Any condition opinion principal investigator would make patient unsuitable enrollment , could interfere patient participate completing study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Hepatitis B Entecavir pegylated interferon a-2a</keyword>
</DOC>